DGAP-News: Delenex Therapeutics AG closes CHF 7.3 (USD 8.0) million Series A3 Financing
(firmenpresse) - EQS Group-News: Delenex Therapeutics AG / Key word(s): Capital
Increase
Delenex Therapeutics AG closes CHF 7.3 (USD 8.0) million Series A3
Financing
29.10.2013 / 15:55
---------------------------------------------------------------------
Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing
New capital will support a phase 2a clinical trial in topical treatment of
psoriasis and advance additional PENTRA(R)Bodies to clinical-stage of
development.
Schlieren/Zurich, Switzerland - October 29, 2013 - Delenex Therapeutics AG,
a biotechnology company developing topical and local treatments for
dermatologic diseases using its proprietary PENTRA(R)Bodies, today
announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All
existing venture investors, HBM Ventures, Novo A/S, SV Life Sciences,
BioMedinvest and Venture Incubator participated in the round. In addition,
minority investors also participated.
These proceeds will primarily be used to:
1. finish a phase 2a clinical study using the anti-TNF?PENTRA(R)Body
DLX105 in psoriasis, with data expected in mid-2014,
2. advance the development of PENTRA(R)Bodies for the treatment of certain
dermatologic diseases towards clinical development, and
3. exploit the PENTRA(R) antibody and technology platform for the
generation of novel products.
This financing round brings Delenex' total capital raised since inception
to CHF 37.6 million.
Executive Chairman Dr. Thomas Hecht said, 'The findings of our ongoing
psoriasis program and progress of earlier-stage projects provide a strong
rationale for supporting additional investments in Delenex' pipeline. We
are confident that we can strengthen our dermatology franchise and also
explore additional therapeutic areas with this continued financial support
by our investors.' CFO Jakob Schlapbach mentioned, 'We are very pleased
that all prior major investors engaged in this financing round on their pro
rata basis. This shows the strong commitment of our investors to the
promise of our products and platform.'
About Delenex Therapeutics AG
Delenex is a privately-held biopharmaceutical company focused on the
development of locally or topically applied antibody therapeutics. Thereby
Delenex aims at extending the
benefits of proven antibody therapeutics to a much larger number of
patients. Delenex' proprietary PENTRA(R) platform will deliver such novel,
potent and safe antibody therapeutics that are well suited for
local/topical application.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a
Novartis company).
For further information, please contact:
Jakob Schlapbach
Chief Financial Officer
Phone: +41 44 730 5180
E-mail: jakob.schlapbach(at)delenex.com
Website: www.delenex.com
End of Corporate News
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=PNRTAICOCP
Document title: 131029 Delenex Press Release
---------------------------------------------------------------------
29.10.2013 This Corporate News was distributed by EQS Schweiz AG.
www.eqs.com - news archive: http://switzerland.eqs.com/de/News
The issuer is responsible for the contents of the release.
---------------------------------------------------------------------
236692 29.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2013 - 15:55 Uhr
Sprache: Deutsch
News-ID 310448
Anzahl Zeichen: 3180
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Delenex Therapeutics AG closes CHF 7.3 (USD 8.0) million Series A3 Financing"
steht unter der journalistisch-redaktionellen Verantwortung von
Delenex Therapeutics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
